Efficacy of Periodontal Surgery on Subgingival Periodontopathogen Levels in Periodontitis Patients: A Randomized Clinical Trial

牙周手术对牙周炎患者龈下致病菌水平的影响:一项随机临床试验

阅读:1

Abstract

OBJECTIVES: This study evaluates the changes in subgingival periodontopathogens following access flap surgery (AFS) in Stage III Grade B periodontitis patients. MATERIALS AND METHODS: This randomized clinical split-mouth study included 20 systemically healthy periodontitis patients. Participants' right and left quadrants were randomly assigned to the control (nonsurgery) or test (AFS) group. Quantities of subgingival periodontopathogens (Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia) and periodontal measurements (gingival index [GI], plaque index [PI], bleeding on probing [BOP], probing depth [PD], and clinical attachment level [CAL]) were evaluated before and 4 weeks after surgery. Quantitative polymerase chain reaction was utilized for detecting and quantifying periodontopathogens. RESULTS: A significant reduction in periodontopathogens was observed in the test group, while levels increased in the control group (p  < 0.05). A significant difference was noted between the groups in changes in the quantities of periodontopathogens (p  < 0.05). The reduction in periodontal parameters was significantly greater in the test group 1-month post-AFS (p  < 0.05). Positive correlations were observed between decreases in P. gingivalis levels and reductions in T. denticola and T. forsythia (p  < 0.05). CONCLUSIONS: AFS effectively reduces subgingival periodontopathogens and enhances periodontal health in the early healing phase. It demonstrates significant benefits for patients with advanced periodontitis and deep residual pockets. CLINICAL RELEVANCE: AFS is an effective treatment option for managing deep residual pockets, as it promotes periodontal health and significantly reduces bacterial burden during the critical early healing phase. These results are particularly valuable for clinicians aiming to prevent disease progression, thereby enhancing patient care and treatment outcomes. Trial Registration: ClinicalTrials.gov identifier: NCT06684288.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。